# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and anti...
Reiterated 2024 Financial OutlookThe Company continues to expect full year 2024 total sepsis product revenue of $10.0 million t...
T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(2.66) per share which missed the analyst consensus estimate of $(2.2...